Investment
Features
FeesSafety
Academy
More
Pluang+

Zcash Foundation denies ties to ZRC-20 and CASH token, warns users to research third-party products.

Market News
21 Sep 2026
Crypto news
View Source
Neutral
Zcash Foundation denies ties to ZRC-20 and CASH token, warns users to research third-party products.

The Zcash Foundation clarified it has no official connection to the ZRC-20 token standard or the CASH token, both developed independently by a third party. The Foundation disavowed a recent social media post that mistakenly presented these as official Zcash network features. ZRC-20 operates by embedding token instructions in encrypted memo fields on Zcash transactions without changing the protocol or requiring formal approval. The Foundation urged users to exercise caution and conduct their own research before engaging with these tokens, especially U.S. investors who must consider regulatory implications. Meanwhile, official Zcash network upgrades continue through formal improvement proposals separate from third-party projects.

The Zcash Foundation's disavowal of the ZRC-20 and CASH tokens provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Sep 21, 2026 22:21 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell. Notable movers include LUNC (Terra Classic) at Rp0,991 with a 9.66% increase and a typical hold time of 193 days, LTC (Litecoin) at Rp1.108.694 up 9.36%, and ADA (Cardano) at Rp4.323 up 9.30%.

More News

Boeing faces 737 MAX production delays but analysts see potential 32% stock upside.

Boeing faces 737 MAX production delays but analysts see potential 32% stock upside.

Boeing is experiencing ongoing production challenges with its 737 MAX aircraft, causing delays and a recent 3.7% stock drop. Jefferies lowered its price target to $265, still implying a 32% upside from current prices, reflecting cautious optimism. Ba...

Analyst Insights
Neutral
38 minutes ago
Alkermes' ALKS7290 shows strong early results in ADHD treatment, boosting stock by 2.3%.

Alkermes' ALKS7290 shows strong early results in ADHD treatment, boosting stock by 2.3%.

Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...

Market News
Bullish
3 hours ago
BrandPilot AI to attend Marketecture Live 2026, focusing on AI and transparency in digital advertising.

BrandPilot AI to attend Marketecture Live 2026, focusing on AI and transparency in digital advertising.

BrandPilot AI announced its participation in Marketecture Live 2026 in Chicago, an event that gathers advertising, media, and technology professionals to discuss industry developments. The company aims to engage in discussions about artificial intell...

Market News
Neutral
4 hours ago
Meta shares jump 12% on strong early adoption of Muse AI assistant and higher price target

Meta shares jump 12% on strong early adoption of Muse AI assistant and higher price target

Meta Platforms shares surged 12% to $747.91 following early success of its new Muse AI assistant, which topped Apple's US App Store with over 730,000 downloads shortly after launch. Wells Fargo raised Meta's price target to $796, citing strong moment...

Market News
Bullish
4 hours ago
Ventas posts strong Q2 2026 growth, raises full-year guidance on senior housing strength.

Ventas posts strong Q2 2026 growth, raises full-year guidance on senior housing strength.

Ventas reported solid Q2 2026 results with 10% same-store cash NOI growth and 9% normalized FFO/share growth, driven by its dominant senior housing portfolio. Management raised its 2026 FFO/share guidance and acquisition targets, citing a strong bala...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App